- Home
- GLP vs NAMS Comparison
GLP vs NAMS Comparison
Compare GLP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLP
- NAMS
- Stock Information
- Founded
- GLP 2005
- NAMS 2019
- Country
- GLP United States
- NAMS Netherlands
- Employees
- GLP N/A
- NAMS N/A
- Industry
- GLP Oil Refining/Marketing
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- GLP Energy
- NAMS Health Care
- Exchange
- GLP Nasdaq
- NAMS Nasdaq
- Market Cap
- GLP 1.7B
- NAMS 1.7B
- IPO Year
- GLP 2005
- NAMS N/A
- Fundamental
- Price
- GLP $49.06
- NAMS $26.75
- Analyst Decision
- GLP Strong Buy
- NAMS Strong Buy
- Analyst Count
- GLP 1
- NAMS 6
- Target Price
- GLP $54.00
- NAMS $36.20
- AVG Volume (30 Days)
- GLP 75.7K
- NAMS 1.4M
- Earning Date
- GLP 11-08-2024
- NAMS 02-06-2025
- Dividend Yield
- GLP 5.94%
- NAMS N/A
- EPS Growth
- GLP N/A
- NAMS N/A
- EPS
- GLP 3.31
- NAMS N/A
- Revenue
- GLP $17,386,440,000.00
- NAMS $33,594,000.00
- Revenue This Year
- GLP $15.01
- NAMS $129.49
- Revenue Next Year
- GLP $30.51
- NAMS N/A
- P/E Ratio
- GLP $14.71
- NAMS N/A
- Revenue Growth
- GLP 5.31
- NAMS 78.77
- 52 Week Low
- GLP $37.00
- NAMS $10.29
- 52 Week High
- GLP $58.77
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- GLP 35.18
- NAMS 68.38
- Support Level
- GLP $52.73
- NAMS $24.40
- Resistance Level
- GLP $56.61
- NAMS $27.29
- Average True Range (ATR)
- GLP 2.17
- NAMS 1.57
- MACD
- GLP -1.09
- NAMS 0.63
- Stochastic Oscillator
- GLP 3.06
- NAMS 94.52
About GLP Global Partners LP Common Units representing Limited Partner Interests
Global Partners LP is an U.S.-based limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.